Please use this identifier to cite or link to this item:
http://sgc.anlis.gob.ar/handle/123456789/1428
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Duschak, Vilma G | es |
dc.date.accessioned | 2019-12-04T18:54:21Z | - |
dc.date.available | 2019-12-04T18:54:21Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 2212-4071 | - |
dc.identifier.uri | http://sgc.anlis.gob.ar/handle/123456789/1428 | - |
dc.description | Fil: Duschak, Vilma G. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina. | es |
dc.description.abstract | The American trypanosomiasis, Chagas disease, is a parasitic infection typically spread by triatomine vectors affecting millions of people all over Latin America. Existing chemotherapy is centered on the nitroaromatic compounds benznidazole and nifurtimox that provide unsatisfactory results and substantial side effects. So, the finding and exploration of novel ways to challenge this neglected disease is a main priority. | es |
dc.language.iso | en | es |
dc.publisher | Bentham Science Publishers | es |
dc.relation.ispartof | Recent patents on anti-infective drug discovery | es |
dc.rights | Closed Access | - |
dc.source | Recent patents on anti-infective drug discovery 2016;11(2):74-173. | - |
dc.subject | Trypanosoma cruzi | es |
dc.subject | Enfermedad de Chagas | es |
dc.subject | Patente | es |
dc.title | Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period | es |
dc.type | Artículo | es |
dc.identifier.doi | 10.2174/1574891X11666161024165304 | - |
anlis.essnrd | 1 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.openairetype | Artículo | - |
item.fulltext | No Fulltext | - |
item.languageiso639-1 | en | - |
Appears in Collections: | Publicaciones INP |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.